These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 31437791)

  • 1. LDC000067 suppresses RANKL-induced osteoclastogenesis in vitro and prevents LPS-induced osteolysis in vivo.
    Xue S; Shao Q; Zhu LB; Jiang YF; Wang C; Xue B; Lu HM; Sang WL; Ma JZ
    Int Immunopharmacol; 2019 Oct; 75():105826. PubMed ID: 31437791
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nirogacestat suppresses RANKL-Induced osteoclast formation in vitro and attenuates LPS-Induced bone resorption in vivo.
    Chen X; Chen X; Zhou Z; Mao Y; Wang Y; Ma Z; Xu W; Qin A; Zhang S
    Exp Cell Res; 2019 Sep; 382(1):111470. PubMed ID: 31211955
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.
    Wu X; Li Z; Yang Z; Zheng C; Jing J; Chen Y; Ye X; Lian X; Qiu W; Yang F; Tang J; Xiao J; Liu M; Luo J
    J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neogambogic Acid Suppresses Receptor Activator of Nuclear Factor κB Ligand (RANKL)-Induced Osteoclastogenesis by Inhibiting the JNK and NF-κB Pathways in Mouse Bone Marrow-Derived Monocyte/Macrophages.
    Jin G; Wang FF; Li T; Jia DD; Shen Y; Xu HC
    Med Sci Monit; 2018 Apr; 24():2569-2577. PubMed ID: 29698379
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Andrographolide suppresses RANKL-induced osteoclastogenesis in vitro and prevents inflammatory bone loss in vivo.
    Zhai ZJ; Li HW; Liu GW; Qu XH; Tian B; Yan W; Lin Z; Tang TT; Qin A; Dai KR
    Br J Pharmacol; 2014 Feb; 171(3):663-75. PubMed ID: 24125472
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diallyl disulfide alleviates inflammatory osteolysis by suppressing osteoclastogenesis
    Yang J; Tang R; Yi J; Chen Y; Li X; Yu T; Fei J
    FASEB J; 2019 Jun; 33(6):7261-7273. PubMed ID: 30857415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PP121 suppresses RANKL-Induced osteoclast formation in vitro and LPS-Induced bone resorption in vivo.
    Zhou Z; Chen X; Chen X; Qin A; Mao Y; Pang Y; Yu S; Zhang S
    Exp Cell Res; 2020 Mar; 388(2):111857. PubMed ID: 31972221
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stachydrine prevents LPS-induced bone loss by inhibiting osteoclastogenesis via NF-κB and Akt signalling.
    Meng J; Zhou C; Zhang W; Wang W; He B; Hu B; Jiang G; Wang Y; Hong J; Li S; He J; Yan S; Yan W
    J Cell Mol Med; 2019 Oct; 23(10):6730-6743. PubMed ID: 31328430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Taxifolin Inhibits Receptor Activator of NF-κB Ligand-Induced Osteoclastogenesis of Human Bone Marrow-Derived Macrophages in vitro and Prevents Lipopolysaccharide-Induced Bone Loss in vivo.
    Zhang HQ; Wang YJ; Yang GT; Gao QL; Tang MX
    Pharmacology; 2019; 103(1-2):101-109. PubMed ID: 30522105
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sanguiin H-6, a constituent of Rubus parvifolius L., inhibits receptor activator of nuclear factor-κB ligand-induced osteoclastogenesis and bone resorption in vitro and prevents tumor necrosis factor-α-induced osteoclast formation in vivo.
    Sakai E; Aoki Y; Yoshimatsu M; Nishishita K; Iwatake M; Fukuma Y; Okamoto K; Tanaka T; Tsukuba T
    Phytomedicine; 2016 Jul; 23(8):828-37. PubMed ID: 27288918
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of tranylcypromine on osteoclastogenesis
    Liu Z; Yang K; Yan X; Wang T; Jiang T; Zhou Q; Qi J; Qian N; Zhou H; Chen B; Huang P; Guo L; Zhang X; Xu X; Jiang M; Deng L
    FASEB J; 2019 Sep; 33(9):9828-9841. PubMed ID: 31291555
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trapidil, a platelet-derived growth factor antagonist, inhibits osteoclastogenesis by down-regulating NFATc1 and suppresses bone loss in mice.
    Kim SD; Kim HN; Lee JH; Jin WJ; Hwang SJ; Kim HH; Ha H; Lee ZH
    Biochem Pharmacol; 2013 Sep; 86(6):782-90. PubMed ID: 23928189
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Scutellarin inhibits RANKL-mediated osteoclastogenesis and titanium particle-induced osteolysis via suppression of NF-κB and MAPK signaling pathway.
    Zhao S; Sun Y; Li X; Wang J; Yan L; Zhang Z; Wang D; Dai J; He J; Wang S
    Int Immunopharmacol; 2016 Nov; 40():458-465. PubMed ID: 27728897
    [TBL] [Abstract][Full Text] [Related]  

  • 14. α-Linolenic Acid Inhibits Receptor Activator of NF-κB Ligand Induced (RANKL-Induced) Osteoclastogenesis and Prevents Inflammatory Bone Loss via Downregulation of Nuclear Factor-KappaB-Inducible Nitric Oxide Synthases (NF-κB-iNOS) Signaling Pathways.
    Song J; Jing Z; Hu W; Yu J; Cui X
    Med Sci Monit; 2017 Oct; 23():5056-5069. PubMed ID: 29061958
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Herbacetin inhibits RANKL-mediated osteoclastogenesis in vitro and prevents inflammatory bone loss in vivo.
    Li L; Sapkota M; Kim SW; Soh Y
    Eur J Pharmacol; 2016 Apr; 777():17-25. PubMed ID: 26923730
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Maslinic acid suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss by regulating RANKL-mediated NF-κB and MAPK signaling pathways.
    Li C; Yang Z; Li Z; Ma Y; Zhang L; Zheng C; Qiu W; Wu X; Wang X; Li H; Tang J; Qian M; Li D; Wang P; Luo J; Liu M
    J Bone Miner Res; 2011 Mar; 26(3):644-56. PubMed ID: 20814972
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protein phosphatase 2A as a new target for downregulating osteoclastogenesis and alleviating titanium particle-induced bone resorption.
    Wang L; Guo X; Zhou W; Ding Y; Shi J; Wu X; Liu Y; Xu Y; Yang H; Geng D
    Acta Biomater; 2018 Jun; 73():488-499. PubMed ID: 29656074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Artesunate inhibits RANKL-induced osteoclastogenesis and bone resorption in vitro and prevents LPS-induced bone loss in vivo.
    Wei CM; Liu Q; Song FM; Lin XX; Su YJ; Xu J; Huang L; Zong SH; Zhao JM
    J Cell Physiol; 2018 Jan; 233(1):476-485. PubMed ID: 28294321
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sappanone A inhibits RANKL-induced osteoclastogenesis in BMMs and prevents inflammation-mediated bone loss.
    Choo YY; Tran PT; Min BS; Kim O; Nguyen HD; Kwon SH; Lee JH
    Int Immunopharmacol; 2017 Nov; 52():230-237. PubMed ID: 28946117
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Myricetin prevents titanium particle-induced osteolysis in vivo and inhibits RANKL-induced osteoclastogenesis in vitro.
    Wu C; Wang W; Tian B; Liu X; Qu X; Zhai Z; Li H; Liu F; Fan Q; Tang T; Qin A; Zhu Z
    Biochem Pharmacol; 2015 Jan; 93(1):59-71. PubMed ID: 25449599
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.